← All trials
NCT07019012
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2025
- Primary completion
- Oct 30, 2026
- Completion date
- Dec 30, 2026
- First posted
- Jun 13, 2025
- Last posted
- Jun 13, 2025
- Enrollment
- 170
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Nanchang UniversityCollaborator
- Wuhan UniversityCollaborator
- Shiyan Taihe HospitalCollaborator
- Xiang Yang NO.1 People's HospitalCollaborator
- Wuhan Central HospitalCollaborator
- Huazhong University of Science and TechnologySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.